drugset / Trial / NCT01299285

Disposition of 14C-LY3009104 Following Oral Administration in Healthy Human Subjects

NCT01299285

Phase 1 Completed 6 enrolled Eli Lilly and Company
NaSingle-groupOpen-labelOther

Summary

This is a single dose study of radiolabeled \[14C\]-LY3009104 in healthy male volunteers to study the absorption, distribution, metabolism, and elimination of LY3009104. This study requires minimum of 7 days and maximum of 22 days stay. This study is for research purposes only and is not intended to treat any medical condition.

Timeline

Start
2011-02
Primary completion
2011-03
Completion
2011-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Baricitinib Small molecule 10 mg Oral

Indications

No indication recorded.